CD8A and plasma cell myeloma: In a phase 1 trial evaluating this DC/myeloma fusion vaccine, vaccination was well tolerated and resulted in expansion of CD4 and CD8 myeloma-reactive T cells and disease stabilization in the majority of patients (143).